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Background: The Modified Shuttle Test (MST) is a valid and sensitive measure of exercise capacity in adult CF patients. Recently, its
validity in children has been demonstrated. The aim of this study was to demonstrate the utility of the MST as a measure of responsiveness to
hospitalisation for i.v. antibiotic and supportive therapy in children and adolescents with CF.
Methods: 28 children and adolescents (40 admissions) performed a MST and lung function within 48 h of admission and discharge to
hospital for administration of intravenous antibiotics. Mean age was 12.7 years and antibiotic therapy length was 14.7 days.
Results: Upon admission, the mean (S.D.) FEV1 was 63 (19)% predicted, FVC was 80 (18)% predicted, FEF25–75 43 (29)% predicted and
MST distance 718 (232) m. FEV1 increased by 15% ( p0.001), FVC by 13% ( p0.001), FEF25–75 by 39% ( p0.001) and MST distance
by 102 m ( p0.001). The percentage improvement in MST distance at 18% ( p0.001) was similar to that for FEV1, but could not be
predicted by the change in FEV1.
Conclusion: This study demonstrated the utility of the MST to assess the effect of hospitalisation for i.v. antibiotic and supportive therapy in
children and adolescents with CF.
D 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Exercise testing; Paediatrics; Exercise tolerance; Physiotherapy; Lung function; Antibiotics1. Introduction
Declining respiratory function, impaired nutritional
status, musculoskeletal complications and other sequelae
of cystic fibrosis (CF) impact significantly on exercise
tolerance, and ultimately an individuals’ ability to perform
normal activities of daily living [1]. Although lung function,
in particular the forced expiratory volume in the first second
(FEV1), is often viewed as the ‘‘Gold Standard’’ measure of
pulmonary disease and expected outcome in CF, predicting
exercise tolerance or functional ability from lung function
results is not always accurate or possible [2–5].1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
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E-mail address: karenm8@chw.edu.au (K.O. McKay).Exercise testing, to determine exercise tolerance and
functional ability, is gaining in importance as a tool for
assessing prognosis [5,6], respiratory morbidity [7,8],
suitability for transplantation [9] and quantifying impact
of disease on quality of life [10]. In addition, exercise
testing has been used to assess the effectiveness of intensive
therapy in both adults and children [11–14]. Formal
exercise testing in appropriate laboratories with exhaled
air analysis provides the most accurate means of measuring
exercise capacity although informal exercise tests can be a
suitable alternative. Informal exercise tests (or field tests),
like the Modified Shuttle Test (MST), provide time-
conscious and inexpensive forms of exercise assessment
which promote a less stressful environment for patients, and
can be undertaken outside of formal testing laboratories
[15,16], thus minimising the need for repeated visits to
major centres for assessment. There is also some evidence5 (2006) 165 – 170ed by Elsevier B.V. All rights reserved.
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exercise assessments such as treadmill tests [16].
The MST is a valid measure of exercise capacity in both
adults [17] and children with CF [18]. The MST evokes a
symptom-limited exercise response in patients with mild as
well as severe pulmonary disease equivalent to that
obtained with a treadmill test [17]. This is in contrast to
the Three-Minute Step Test, which in children, has been
shown to be sub-maximal in nature [19]. The MST is
portable and easily administered and can be conducted in
limited space. It has been noted that the MST is externally
paced, thus providing increased motivation to subjects,
removes tester influence and is more representative of
patterns of daily childhood activity than formal laboratory-
based exercise tests [20].
MST performance in adults with CF has been shown to
be highly responsive to intravenous antibiotic-induced
changes in disease status [15]. As yet, the accuracy of the
MST in detecting changes in exercise tolerance, as a result
of intensive therapy such as that occurring during a
hospitalisation for intravenous (i.v.) antibiotic treatment in
children with CF, has not been determined.
We hypothesized that the MST would be a useful
measure of the effect of hospitalisation for i.v. antibiotic
and supportive therapy (i.e. airway clearance, dietary
optimisation, medication management, social support, in-
tensive medical review, assistance with schooling). As such,
the aim of this study was to establish, in children and
adolescents with CF, the magnitude of the change in
distance travelled during the MST over the course of
hospitalisation, as well as the magnitude of change in
spirometric lung function. In addition, we sought to
ascertain whether the magnitude of improvement in MST
distance was dependent on baseline exercise capacity and
was related to improvement in FEV1.2. Materials and methods
The study population consisted of children and adoles-
cents with CF admitted to The Children’s Hospital at
Westmead for i.v. antibiotic and supportive therapy for a
period of at least 10 days. All were admitted due to
respiratory exacerbations characterised by signs and symp-
toms including decreased pulmonary function, new infil-
trates on chest X-ray, increased cough, breathlessness,
change in sputum production (colour and/or quantity),
malaise and weight loss. None of the admissions were for
routine scheduled courses of IV antibiotics. All participants
had been diagnosed with CF by way of a newborn screening
programme and only one was pancreatic sufficient. Only
those who had previously performed an exercise test, lung
function testing and who did not require supplemental
oxygen were invited to join in the study. Ethics approval for
this study was obtained from The Children’s Hospital at
Westmead Ethics Committee, which advised that individualwritten consent was not necessary for this study as exercise
testing by means of the MST and spirometry were part of the
existing care plan for CF.
All subjects performed lung function testing, and
completed a MSTwithin 48 h of admission to and discharge
from hospital. The i.v. antibiotic therapy consisted of two
antibiotics (one usually being an aminoglycoside), the
particular antibiotics being chosen based upon the sensitiv-
ity patterns of bacteria obtained from sputum cultures and
prior clinical improvement. The participant with MRSAwas
treated with a combination of three i.v. antibiotics (vanco-
mycin, meropenem and tobramycin). The duration of the
course was generally 14 days, except when there had been
insufficient improvement in the opinion of the respiratory
consultant involved and an extension of up to 7 days
occurred. During the admission, each participant received
review by a dietician and social worker as well as daily
physiotherapy consisting of both an airway clearance
technique and an exercise session. All subjects performed
positive expiratory pressure (PEP) as their airway clearance
technique. Exercise sessions were undertaken by all
participants and performed under the supervision of a
physiotherapist. Exercise sessions were of 20–30 min
duration and comprised aerobic activity (particularly tread-
mill) and low load upper and lower limb strengthening
exercises.
Lung function was measured by an experienced scientific
officer using a Vmax 22D spirometer coupled to an
Autobox V62J Body Plethysmograph and Spectra software
(Sensormedics Corp., Yorba Linda, CA, USA) in accor-
dance with American Thoracic Society guidelines, and the
results were expressed as a percentage of that predicted by
Polgar and Promadhat [21]. All participants had been
performing lung function frequently since the age of 5 and
were technically proficient in terms of the required
manoeuvres.
The MST was administered by a physiotherapist familiar
with the test as described by Bradley et al. [15]. The
modified test has 15 levels and allows subjects to run as
necessary. The test requires participants to move around two
markers over a 10 m course in time with ‘‘beeps’’ from a
pre-recorded tape. Each level in the test lasts for 1 min, with
the speed of the test increasing by 0.61 km/h each minute.
There are a maximum of 15 levels. The test is concluded
when participants state subjectively that they are unable to
continue or fail to make the course marker on two
consecutive beeps.
Heart rate (HR) and oxygen saturation (by pulse
oximetry, SaO2) were measured before and after the MST
using a finger probe (Datex, Ohmeda TuffSat, Madison, WI,
USA). Participants were also asked to give a rating of their
perceived exertion (RPE) using The Children’s Hospital
RPE scale (Fig. 1). This is a validated six-point scale, which
ranges from 0 (not tired at all) to 5 (absolutely exhausted,
could not possibly continue with exercise) [22]. In addition
to numerical and written prompts, the scale has visual cues
Fig. 1. Rate of perceived exertion scale.
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distress.
The age of subjects ranged from 7.6 to 17.6 years (mean
12.7 years). As with most CF subjects, the participants were
below average height with a mean height z-score of 1.02
(range 3.71 to 0.96) and were also below average weight
with a mean weight z-score of 1.04 (range 2.86 to 0.26).
Seventy-eight percent of those participating isolated Pseu-
domonas aeruginosa upon sputum culture at the time of
admission to hospital and 11% grew Staphylococcus aureus
(all of whom had repeatedly isolated P. aeruginosa upon
sputum culture within the previous 12 months). The
remainder of the participants had neither of these bacteria
but had Stenotrophomonas maltophilia (this participant had
isolated P. aeruginosa repeatedly upon sputum culture
within the previous 6 months), MRSA or a coliform species
(this participant had isolated P. aeruginosa upon sputumTable 1
Lung function and MST distance at admission to and discharge from hospital
Admission mean (range)
FEV1 (l) 1.52 (0.81–3.13)
FEV1 (% predicted) 63 (36–114)
FVC (l) 2.10 (0.91–4.36)
FVC (% predicted) 80 (43–127)
FEF25 – 75 (l/s) 1.13 (0.24–3.32)
FEF25 – 75 (% predicted) 43 (9–121)
MST distance (m) 718 (340–1530)
Significant changes between discharge and admission are shown: *p0.005, **p
a Change from admission to discharge=100 ([valuedischargevalueadmission]vculture one month prior to admission). The mean length of
hospitalisation for i.v. antibiotic and supportive therapy was
14.7 days (range 10–22 days).
Results are expressed as mean values with ranges or stan-
dard deviations. The percentage change in parameters mea-
sured at admission and discharge were computed as follows:
100 ([valuedischargevalueadmission]valueadmission). Per-
centage maximal heart rate was calculated as follows:
100 (HR [220age in years]). The relationship between
pulmonary function measured by spirometry and exercise
capacity measured by the MST, at admission and discharge,
as well as the relationship between the magnitude of
improvement in MST distance and baseline MST distance,
were assessed by calculating the Pearson’s correlation
coefficient and the related statistical significance of these
values. The proportion of individuals with a clinically
relevant improvement in FEV1 (defined as an improvement
from baseline of 10%) and an improvement in MST
distance (of at least 10% from baseline) was compared
using crosstabs and chi-squared analysis. Differences in
mean values were analysed for statistical significance using
paired two-tailed Student’s t-tests. The software package
utilised was SPSS for Windows version 11.5.1 (SPSS Inc.,
Chicago, IL, USA). A value of p <0.05 was considered
significant.3. Results
Twenty-eight children and adolescents (6 male) provided
40 sets of complete data. At the commencement of
hospitalisation, the mean (S.D.) FEV1 was 63 (19)%
predicted with a range of 36% to 114%, forced vital
capacity (FVC) was 80 (18)% predicted and forced
expiratory flow25–75 (FEF25–75) was 43 (29)% predicted.
The mean MST distance was 718 (232) m ranging from 340
m to 1530 m (see Table 1). Admission MST distance
correlated significantly with FEV1 and % predicted FEV1
(r =0.663, p <0.001 and r =0.416, p <0.01, respectively),
FVC and % predicted FVC (r =0.590, p <0.001 and
r =0.420, p <0.01, respectively), as well as FEF25–75 and
% predicted FEF25–75 (r =0.489, p0.001 and r=0.360,
p <0.05, respectively).Discharge mean (range) % Changea mean (range)
1.74 (0.94–4.25)** 15 ( 9 to 58)
71 (42–118)** 15 ( 13 to 57)
2.33 (1.22–5.37)** 13 ( 9 to 144)
87 (56–136)** 11 ( 35 to 107)
1.43 (0.54–3.94)** 39 ( 41 to 221)
51 (20–142)* 33 ( 43 to 122)
820 (500–1530)** 18 ( 26 to 118)
0.001 paired two-tailed Student’s t-test.
alueadmission).
0200
400
600
800
1000
1200
1400
1600
0 20 40 60 80 100 120
FEV1 (% predicted)
M
ST
 d
ist
an
ce
 (m
)
admission
discharge
Fig. 2. The relationship between FEV1 and MST distance at admission and discharge.
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lung function parameters, as well as MST distance over the
period of hospitalisation (Table 1 and Fig. 2). Mean FEV1
improved by 15% (range of improvement 9% to 58%,
p0.001). FVC increased by 13% (range of improvement
9% to 144%, p0.001), while small airway function, as
measured by FEF25–75, also improved significantly (39%
increase, range of improvement 41% to 221%, p0.001).
Mean distance covered in the MST improved by 18% or
102 m (range of improvement 26% to 118%, p0.001)
over the course of hospitalisation. There was a statistically
significant negative correlation between the % improvement
in MST distance and baseline MST distance (r =0.455,
p <0.05) such that those with higher baseline MST distances
had lower improvements in their MST distance from
admission to discharge and, conversely, those with lower
exercise performance at baseline had a greater improvement
over the course of their admission (Fig. 2).
An improvement of at least 5% in MST distance from
baseline was seen in 75% of the study cohort, while an
improvement of at least 10% from admission to discharge-40
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Fig. 3. The relationship between change in % predicted FEwas seen in 60%. Of the 23 occasions on which a subject
had an improvement in FEV1 of 10%, there were 15
occasions when the subject also had an improvement in
MST distance of at least 10% (Fig. 3). Chi-squared analysis
of these frequencies indicated that they were not statistically
significantly related.
Measurement of HR, SaO2 and RPE indicated that the
MST elicited a significant elevation in HR and RPE during
this exercise test (Table 2). HR on admission increased from
a mean of 104 bpm at rest immediately prior to the MST to
141 bpm at the end of exercise. A similar increase was seen
at discharge and these heart rates were such that children
were exercising at approximately 2/3 (68% admission and
70% discharge) the maximal rate predicted for their age.
Similarly, the mean RPE score at the end of exercise was 2.8
on admission and 3.2 at discharge (Fvery tired_) a significant
increase from that at baseline, which was 0.7 on admission
and 0.6 on discharge (between Fnot tired at all_ and Fa little
bit tired_). The safety of the MST was demonstrated by the
finding that the mean SaO2 at end of the MST was only 1%
lower than that at baseline, although this was a statistically30 40 50 60
 in FEV1
V1 and MST distance from admission to discharge.
Table 2
Oxygen saturation (SaO2), heart rate (HR) and rate of perceived exertion
(RPE) before and after MST
Admission Discharge
Rest End-exercise Rest End-exercise
SaO2 (%) 96 (1.4) 95 (3.5)** 97 (1.7) 96 (2.3)*.
HR (bpm) 104 (16) 141 (28)*** 100 (18) 147 (25)***
HR (%maxa) 50 (8) 68 (14)*** 48 (9) 71 (12)***
RPE 0.7 (0.7) 2.9 (1.0)*** 0.6 (0.7) 3.2 (1.1)***
Significant changes between rest and end-exercise values are shown:
*p0.05, **p0.01, ***p0.0001—paired two-tailed Student’s t-test.
Significant changes between admission and discharge values are shown:
.p0.05—paired two-tailed Student’s t-test.
a Calculated from 220age.
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resting RPE, end-exercise HR and end-exercise RPE to
decrease from admission to discharge (Table 2), none of
these decreases were statistically significant. There was a
statistically significant increase in end-exercise SaO2
between admission and discharge although resting SaO2
did not change significantly.4. Discussion
This study has clearly demonstrated improvement in both
MST distance and lung function after hospitalisation for i.v.
antibiotic and supportive therapy. Improvement in MST
distance was dependent on baseline exercise capacity in that
those with lower MST distances at baseline had propor-
tionally greater increases in MST distance from admission
to discharge. The magnitude of the increase in MST distance
could not however be predicted by the increase in FEV1.
The mean increase in FEV1 of 15% demonstrated in this
study is almost identical to the 14% increase observed by
Pike et al. after a 10–14-day course of intravenous
antibiotics [13], thus suggesting that our cohort of subjects
were similar to some of those previously studied. In addition
to the statistically significant increase in all lung function
parameters, however, we have also shown for the first time,
a concomitant increase in MST distance. Where spirometry
is an assessment of airway function and thus flow limitation,
the MST assesses functional capacity, which is influenced
by not only ventilatory function but also cardiovascular,
muscular and metabolic factors. Thus, it would seem that
while there are presently no reference values for assessing
an individual MST result, change in MST performance may
be a suitable measure of the effect of hospitalisation for i.v.
antibiotic and supportive therapy.
Our findings of an increase in exercise performance after
in hospital therapy are by no means the first. In 1984, Cerny
et al. showed that exercise capacity, as measured by cycle
ergometry, increased significantly in a group of subjects
with moderate to severe lung disease [11]; in 1988, an
improvement in the 2-min walking distance was reported
[14], while more recently, Pike et al. have also shown animprovement in exercise tolerance as measured by the 3-min
step test [13]. As the MST constitutes an inexpensive,
portable and easily administered test, which can be
conducted in limited space, we believe that MST distance
could be utilized as an adjunct or alternative outcome
measure to pulmonary function testing where formal
exercise testing equipment is unavailable.
The MST was selected as the exercise test of choice
ahead of other validated field tests, for a number of reasons
including those mentioned above. Previous work with the
20-m shuttle in children with CF has been in stable, non-
hospitalized subjects [16]. Space restrictions and a concern
that the 20-m shuttle run test [23] would prove too taxing
for children experiencing a pulmonary exacerbation pre-
cluded the use of that test. The MST also provides a single
test to be used across all ages and disease severity, where the
20-m shuttle is suggested for use in older healthier children
[16,24]. The 6-min walk test [25] and step test [4] are both
valid exercise test measures in children with CF. However,
the self-paced nature of the 6-min walk makes it sub-
maximal and prone to variable motivation, while the step
test is not reflective of a normal functional task and is
unable to measure aerobic capacity. Our observation of a
statistically significant increase in heart rate to at least two
thirds of the maximal rate predicted for age and a three- (on
admission) to five-fold (at discharge) increase in RPE
indicated that the MST elicited a change in the parameters
usually indicative of a maximal exercise and thus confirm-
ing that the MST has overcome the lack of maximal
response elicited in adult CF patients undertaking the
original 12-level shuttle walk test [17].
The progressive nature of the MST and the option to run
are characteristics of the MST, which suggest that it may be
suitable for assessing response in patients with a range of
disease severity. This facet is particularly pertinent in
children and adolescents many of whom have little
functional impairment. We did not detect significant
changes in resting HR, RPE or SaO2 from admission to
discharge in our group and, although the subjects were able
to exercise to a greater extent at discharge, only the end-
exercise SaO2 was improved significantly at discharge. In
the present study, baseline FEV1 % predicted ranged from
36% to 114% predicted upon admission. While about 25%
of our subjects had moderately severe lung disease (as
indicated by a FEV1 less than 50% predicted on admission),
our group was, as a whole, less impaired than those children
studied previously where these indicators of exercise
capacity have improved after therapy [11]. Moreover, while
those in our cohort with lower exercise capacity on
admission did improve more than those with good exercise
tolerance on admission, we did measure increases in MST
performance in children with well-preserved lung function.
In an earlier study in adults with CF, a change in MST
distance of at least 40 m was considered clinically
significant [15]. A clinically significant improvement in
FEV1 is generally considered to be that of greater than or
N.S. Cox et al. / Journal of Cystic Fibrosis 5 (2006) 165–170170equal to 10% and this was achieved for 60% of the
hospitalisations in our study. We thus reasoned that an
increase in MST distance of at least 10% may also constitute
a clinically significant improvement in exercise capacity. In
our study population, we found that 60% of the subjects had
such an increase. Interestingly, however, there were only
37.5% of occasions when subjects had a 10% or greater
improvement in both parameters. This fact highlights the
important point that the magnitude of improvement in MST
distance could not be predicted from the improvement in
FEV1. It also indicates that, although not the subject of this
study, ascertainment of what constitutes a clinically signif-
icant improvement in exercise capacity is required.
Participants in the current study were all experienced in
performing the MST. As such, a practice test was not
undertaken in accordance with the findings of previous
work [15], which suggested adult CF patients would be less
likely to comply with testing procedures if additional
practice tests were required. Consequently, although in our
study, the MST took 20–25 min to complete (including
preparation and patient recovery time), in centres where this
test is not established, and where patients are naı¨ve to the
MST, a practice test is likely to be necessary, and thus the
time required for testing, at least initially, may be
considerably longer. The participants in this study all
enjoyed performing this test and our study population
included a reasonable proportion of adolescent females who
are often loathe to undertake such activities. Nevertheless,
the test is motivation dependent and may not be as useful in
populations where motivation is sub-optimal or where the
children are much sicker than our cohort and thus reluctant
to perform the test. In addition, as the MST requires
movement of the subject and any accompanying equipment,
unlike formal exercise tests where the equipment is
stationary, the MST is not a suitable test for any patient
requiring oxygen or respiratory support, such as non-
invasive ventilation, for exercise.
The results of our study show that MST distance is a
useful measure of exercise capacity and improves after
hospitalisation for i.v. antibiotic and supportive therapy in
children and adolescents with CF. It provides an alternative
clinical outcome measure when formal exercise testing is
not possible and is a complimentary measurement to lung
function testing procedures in paediatric populations.Acknowledgements
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